CONFIDENTIAL AMENDED AND RESTATED DEFINITIVE FINANCING COMMITMENT TERM SHEET TO PROVECTUS BIOPHARMACEUTICALS, INC. DATED EFFECTIVE: March 19, 2017 (May 10th, 2017)
The following is a summary of the terms and conditions of a proposed financing plan (the Plan) offered by certain individuals to Provectus Biopharmaceuticals, Inc. (the Company). The Plan supersedes the proposal to the Board of Directors (the Board) dated March 2, 2017 and made by Transition Advisory Team to the Company on March 3, 2017. Solely for ease of reference in this Term Sheet, the Transition Advisory Team shall hereinafter be referred to as the PRH Group. The PRH Group specifically disclaims that it is a Group as defined in the Federal securities laws. It is the goal of the PRH Group to work with the Company to rebuild and reestablish confidence in the Company and the Companys ability to execute a strategic business plan that maximizes shareholder value with the Company as an ongoing operating enterprise.
Independent Contractor Agreement (April 22nd, 2016)
THIS AGREEMENT is made and entered by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware corporation (the "Company") and JOHN R. GLASS, an Illinois citizen ("Contractor"). Collectively the Company and the Contractor shall be referred to herein as "the Parties."
Notice of Filing (August 7th, 2014)
The Defendants, H. Craig Dees, Timothy C. Scott, Eric A. Wachter and Peter R. Culpepper, (Officer Defendants) who are currently serving officers of Nominal Defendant, Provectus Biopharmaceuticals, Inc. f/k/a Provectus Pharmaceuticals, Inc. give notice, pursuant to the deadlines established in the pleadings served by the Special Litigation Committee on May 7 and May 8, 2014, of the filing of settlement agreements signed by the Officer Defendants.